Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease

a study on Kidney Disease

Summary

Eligibility
for people ages 10-65 (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around

Description

Summary

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.

Official Title

A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease

Keywords

Proteinuric Kidney Disease, Kidney Diseases, VX-147

Eligibility

You can join if…

Open to people ages 10-65

You CAN'T join if...

Other protocol defined Inclusion/Exclusion criteria apply.

Locations

  • UCLA Division of Nephrology completed
    Los Angeles California 90095 United States
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center accepting new patients
    Torrance California 90502 United States
  • Cedars-Sinai Medical Center accepting new patients
    Los Angeles California 90048 United States
  • Kaiser Permanente - Los Angeles Medical Center accepting new patients
    Los Angeles California 90027 United States
  • Amicis Research Center accepting new patients
    Granada Hills California 91344 United States
  • Renal Consultants Medical Group accepting new patients
    Granada Hills California 91344 United States
  • Eastside Clinical Research Associates accepting new patients
    Los Angeles California 90022 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Vertex Pharmaceuticals Incorporated
ID
NCT05312879
Phase
Phase 2/3 Kidney Disease Research Study
Study Type
Interventional
Participants
Expecting 466 study participants
Last Updated